The news of collaboration with Indian Institute of Technology Guwahati to work on developing vaccine against COVID-19 brought luck to Hester Biosciences’ luck. On Wednesday, this smallcap company’s shares hit the upper circuit.
The agreement between the two parties was signed on April 15 and the vaccine will be based on recombinant avian paramyxovirus vector platform. IIT Guwahati and Hester Biosciences Limited expect the vaccine to be ready by the end of this year to start animal studies. The work is currently in its early stage of development.
The team at IIT Guwahati is headed by Dr. Sachin Kumar, Associate Professor, Department of Biosciences and Bioengineering. They have generated the recombinant avian paramyxovirus-1 based vaccine platform for Classical Swine Fever and Japanese encephalitis. The role of the Institute is to produce the recombinant vaccine candidate.
Speaking about the collaboration, Rajiv Gandhi, CEO and MD, Hester Biosciences Limited, said, “IITG & Hester have collaborated to develop and manufacture a recombinant vaccine against COVID-19 disease as a preventive measure. Hester’s involvement would be from master seed development up to release of the commercial vaccine”.